Emtricitabine

證據等級: L5

預測適應症: 3 個

Emtricitabine: From HIV Infection to Feline Acquired Immunodeficiency Syndrome

One-Sentence Summary

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and a cornerstone of combination antiretroviral therapy (cART) for human HIV infection globally. The TxGNN model’s top prediction is Feline Acquired Immunodeficiency Syndrome (FIV), with only 1 veterinary study directly supporting this direction; the 4 retrieved clinical trials are all human HIV-1 trials that were incorrectly mapped and carry no direct relevance to FIV. This candidate is currently rated L4 (animal/preclinical evidence only) and carries a Hold recommendation pending species-specific data.

Quick Overview

Item	Content
Original Indication	HIV infection (NRTI component of combination antiretroviral therapy)
Predicted New Indication	Feline Acquired Immunodeficiency Syndrome
TxGNN Prediction Score	99.92%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on well-established pharmacology, emtricitabine (FTC) is a synthetic fluorinated cytidine analogue. After intracellular phosphorylation to its active triphosphate form (FTC-TP), it acts as a competitive inhibitor of viral reverse transcriptase (RT) and causes premature termination of the growing viral DNA chain — halting viral replication at a critical enzymatic step. Its efficacy against HIV-1, HIV-2, and hepatitis B has been validated across decades of clinical use.

Feline Immunodeficiency Virus (FIV) and HIV are both members of the genus Lentivirus within family Retroviridae, and both cause progressive CD4⁺ T-cell depletion and immune failure. Like HIV, FIV is absolutely dependent on its reverse transcriptase for replication, which is why NRTI-based therapy is mechanistically applicable in principle. The 2023 study by Kim et al. directly tested a cART regimen including emtricitabine (40 mg/kg) in FIV-infected domestic cats, providing the first in vivo proof-of-concept in the target species.

That said, meaningful caveats remain: the RT amino acid sequences of FIV and HIV differ at key positions, potentially affecting drug-binding affinity. Pharmacokinetics in cats diverge substantially from humans — feline metabolism, renal handling, and volume of distribution must be independently characterized before any efficacy claim can be made. This prediction is mechanistically coherent but empirically immature.

Clinical Trial Evidence

⚠️ Mapping Alert: All 4 trials below are human HIV-1 clinical trials. They contain emtricitabine as part of a combination regimen but were retrieved because the search engine matched on “emtricitabine + HIV” keywords rather than FIV-specific evidence. None are designed for or applicable to Feline Acquired Immunodeficiency Syndrome. They are listed solely for transparency and should carry zero evidentiary weight for this indication.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01263015	Phase 3	Completed	844	Dolutegravir + ABC/3TC vs Efavirenz/FTC/TDF (Atripla) in ART-naïve HIV-1 adults over 96 weeks — human HIV-1 trial, not FIV-relevant
NCT02770508	Phase 4	Completed	145	Boosted darunavir + 3TC vs darunavir + FTC/TDF in naïve HIV-1 patients — human HIV-1 trial, not FIV-relevant
NCT01227824	Phase 3	Completed	828	Dolutegravir vs Raltegravir with dual NRTI backbone (ABC/3TC or TDF/FTC) in HIV-1 naïve adults over 96 weeks — human HIV-1 trial, not FIV-relevant
NCT00951015	Phase 2	Completed	208	Once-daily dolutegravir dose-selection study with ABC/3TC or TDF/FTC in HIV-1 naïve adults — human HIV-1 trial, not FIV-relevant

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37112803	2023	Animal / Veterinary Study	Viruses	Evaluated pharmacokinetics and clinical outcomes of cART (Dolutegravir 2.5 mg/kg + Tenofovir 20 mg/kg + Emtricitabine 40 mg/kg) in FIV-infected domestic cats; assessed changes in CD4⁺/CD8⁺ T-cell immunophenotype — the only direct in vivo evidence for FTC use in FIV to date

Philippines Market Information

Emtricitabine is currently not registered in the Philippines. No product license or authorization records are available from the FDA Philippines database.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Only one veterinary animal study directly supports this indication, and all 4 clinical trials retrieved were incorrectly mapped human HIV-1 studies with no bearing on FIV; the evidence base is insufficient to support any clinical, regulatory, or commercial action at this stage. Furthermore, this is a veterinary indication (domestic cats), which falls outside the scope of human medicine and the Philippines FDA’s human drug registration pathway.

To proceed, the following is needed:

Species-specific studies: Formal feline pharmacokinetic and pharmacodynamic studies to establish safe and effective FTC dosing in cats
Controlled veterinary trials: Randomized controlled trials in FIV-infected cats with defined efficacy endpoints (viral load, CD4⁺ count, clinical progression)
MOA confirmation: Retrieve emtricitabine mechanism of action data from DrugBank (DB00879) to document FIV RT binding affinity vs. HIV RT
Safety data: Drug interactions and toxicity monitoring parameters specific to the feline species
Regulatory scoping: If veterinary use is the intended pathway, engage the Bureau of Animal Industry (BAI) of the Philippines rather than FDA Philippines

📌 Note on Other Predicted Indications: The TxGNN model also predicted Simian Immunodeficiency Virus (SIV) infection at rank 2 (score 99.92%, L3 evidence, 20 primate publications including multiple Tier 1 macaque challenge studies directly using FTC/TDF regimens — a “Research Question” recommendation). This represents the stronger preclinical evidence base, as the SHIV macaque model is an FDA-recognized platform for HIV PrEP development and mechanistically translates more directly to human clinical research. A rank 3 prediction for a neurodevelopmental disorder (L5, no evidence) is currently speculative and does not warrant further evaluation.

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.